Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants

Pierre E. Wallemacq, Raymond Reding, Etienne M. Sokal, Jean Ville De De Goyet, Stéphane Clement De Clety, Véronique Van Leeuw, Marc De Backer, Jean Bernard Otte

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Pediatric liver transplant recipients constitute a population characterized by a particularly unpredictable and poor bioavailability of cyclosporin (CyA). Even though several adult studies show that the new oral formulation of CyA, Neoral (NEO), produces better bioavailability and blood level predictability, few data describe its pharmacokinetics in children. We performed a complete analysis of the pharmacokinetics of NEO in ten small children after primary liver transplantation. Three pharmacokinetic profiles were set up with data obtained from tests taken during i.v. administration of CyA, after the first oral NEO dose, and after the last NEO dose before discharge from the hospital. The mean half-lives obtained were 8.1, 7.7, and 6.9 h, respectively, and the bioavailabilities were 22% and 21% for the first and last NEO doses. A large interpatient variability was observed. This was due, in part, to episodes of diarrhea that interfered with the pharmacokinetic evaluation and, in part, to the variability of post-transplant hepatic function. There was a good correlation between CyA trough levels and their related AUCs for both NEO profiles (r = 0.93 and r = 0.74, respectively). We conclude that, even though the pediatric OLT population remains more unpredictable than that of adults, NEO has a relatively rapid half-life and a remarkably improved bioavailability.

Original languageEnglish
Pages (from-to)466-470
Number of pages5
JournalTransplant International
Volume10
Issue number6
DOIs
Publication statusPublished - Nov 1997

Fingerprint

Cyclosporine
Pharmacokinetics
Pediatrics
Transplants
Liver
Biological Availability
Liver Transplantation
Population
Area Under Curve
Half-Life
Diarrhea

Keywords

  • Liver transplantation, pediatric, Neoral
  • Neoral, liver transplantation, pediatric
  • Pediatric liver transplantation, Neoral, pharmacokinetics
  • Pharmacokinetics, Neoral, pediatric liver transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Wallemacq, P. E., Reding, R., Sokal, E. M., De Goyet, J. V. D., De Clety, S. C., Van Leeuw, V., ... Otte, J. B. (1997). Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants. Transplant International, 10(6), 466-470. https://doi.org/10.1007/s001470050088

Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants. / Wallemacq, Pierre E.; Reding, Raymond; Sokal, Etienne M.; De Goyet, Jean Ville De; De Clety, Stéphane Clement; Van Leeuw, Véronique; De Backer, Marc; Otte, Jean Bernard.

In: Transplant International, Vol. 10, No. 6, 11.1997, p. 466-470.

Research output: Contribution to journalArticle

Wallemacq, PE, Reding, R, Sokal, EM, De Goyet, JVD, De Clety, SC, Van Leeuw, V, De Backer, M & Otte, JB 1997, 'Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants', Transplant International, vol. 10, no. 6, pp. 466-470. https://doi.org/10.1007/s001470050088
Wallemacq PE, Reding R, Sokal EM, De Goyet JVD, De Clety SC, Van Leeuw V et al. Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants. Transplant International. 1997 Nov;10(6):466-470. https://doi.org/10.1007/s001470050088
Wallemacq, Pierre E. ; Reding, Raymond ; Sokal, Etienne M. ; De Goyet, Jean Ville De ; De Clety, Stéphane Clement ; Van Leeuw, Véronique ; De Backer, Marc ; Otte, Jean Bernard. / Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants. In: Transplant International. 1997 ; Vol. 10, No. 6. pp. 466-470.
@article{39bba5c43dbd4900a2445892aa8a19f1,
title = "Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants",
abstract = "Pediatric liver transplant recipients constitute a population characterized by a particularly unpredictable and poor bioavailability of cyclosporin (CyA). Even though several adult studies show that the new oral formulation of CyA, Neoral (NEO), produces better bioavailability and blood level predictability, few data describe its pharmacokinetics in children. We performed a complete analysis of the pharmacokinetics of NEO in ten small children after primary liver transplantation. Three pharmacokinetic profiles were set up with data obtained from tests taken during i.v. administration of CyA, after the first oral NEO dose, and after the last NEO dose before discharge from the hospital. The mean half-lives obtained were 8.1, 7.7, and 6.9 h, respectively, and the bioavailabilities were 22{\%} and 21{\%} for the first and last NEO doses. A large interpatient variability was observed. This was due, in part, to episodes of diarrhea that interfered with the pharmacokinetic evaluation and, in part, to the variability of post-transplant hepatic function. There was a good correlation between CyA trough levels and their related AUCs for both NEO profiles (r = 0.93 and r = 0.74, respectively). We conclude that, even though the pediatric OLT population remains more unpredictable than that of adults, NEO has a relatively rapid half-life and a remarkably improved bioavailability.",
keywords = "Liver transplantation, pediatric, Neoral, Neoral, liver transplantation, pediatric, Pediatric liver transplantation, Neoral, pharmacokinetics, Pharmacokinetics, Neoral, pediatric liver transplantation",
author = "Wallemacq, {Pierre E.} and Raymond Reding and Sokal, {Etienne M.} and {De Goyet}, {Jean Ville De} and {De Clety}, {St{\'e}phane Clement} and {Van Leeuw}, V{\'e}ronique and {De Backer}, Marc and Otte, {Jean Bernard}",
year = "1997",
month = "11",
doi = "10.1007/s001470050088",
language = "English",
volume = "10",
pages = "466--470",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Blackwell Publishing Ltd",
number = "6",

}

TY - JOUR

T1 - Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants

AU - Wallemacq, Pierre E.

AU - Reding, Raymond

AU - Sokal, Etienne M.

AU - De Goyet, Jean Ville De

AU - De Clety, Stéphane Clement

AU - Van Leeuw, Véronique

AU - De Backer, Marc

AU - Otte, Jean Bernard

PY - 1997/11

Y1 - 1997/11

N2 - Pediatric liver transplant recipients constitute a population characterized by a particularly unpredictable and poor bioavailability of cyclosporin (CyA). Even though several adult studies show that the new oral formulation of CyA, Neoral (NEO), produces better bioavailability and blood level predictability, few data describe its pharmacokinetics in children. We performed a complete analysis of the pharmacokinetics of NEO in ten small children after primary liver transplantation. Three pharmacokinetic profiles were set up with data obtained from tests taken during i.v. administration of CyA, after the first oral NEO dose, and after the last NEO dose before discharge from the hospital. The mean half-lives obtained were 8.1, 7.7, and 6.9 h, respectively, and the bioavailabilities were 22% and 21% for the first and last NEO doses. A large interpatient variability was observed. This was due, in part, to episodes of diarrhea that interfered with the pharmacokinetic evaluation and, in part, to the variability of post-transplant hepatic function. There was a good correlation between CyA trough levels and their related AUCs for both NEO profiles (r = 0.93 and r = 0.74, respectively). We conclude that, even though the pediatric OLT population remains more unpredictable than that of adults, NEO has a relatively rapid half-life and a remarkably improved bioavailability.

AB - Pediatric liver transplant recipients constitute a population characterized by a particularly unpredictable and poor bioavailability of cyclosporin (CyA). Even though several adult studies show that the new oral formulation of CyA, Neoral (NEO), produces better bioavailability and blood level predictability, few data describe its pharmacokinetics in children. We performed a complete analysis of the pharmacokinetics of NEO in ten small children after primary liver transplantation. Three pharmacokinetic profiles were set up with data obtained from tests taken during i.v. administration of CyA, after the first oral NEO dose, and after the last NEO dose before discharge from the hospital. The mean half-lives obtained were 8.1, 7.7, and 6.9 h, respectively, and the bioavailabilities were 22% and 21% for the first and last NEO doses. A large interpatient variability was observed. This was due, in part, to episodes of diarrhea that interfered with the pharmacokinetic evaluation and, in part, to the variability of post-transplant hepatic function. There was a good correlation between CyA trough levels and their related AUCs for both NEO profiles (r = 0.93 and r = 0.74, respectively). We conclude that, even though the pediatric OLT population remains more unpredictable than that of adults, NEO has a relatively rapid half-life and a remarkably improved bioavailability.

KW - Liver transplantation, pediatric, Neoral

KW - Neoral, liver transplantation, pediatric

KW - Pediatric liver transplantation, Neoral, pharmacokinetics

KW - Pharmacokinetics, Neoral, pediatric liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=0030844126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030844126&partnerID=8YFLogxK

U2 - 10.1007/s001470050088

DO - 10.1007/s001470050088

M3 - Article

VL - 10

SP - 466

EP - 470

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 6

ER -